139 related articles for article (PubMed ID: 9056157)
1. Safety profile of new non-ionic contrast media: renal tolerance.
Stacul F; Thomsen HS
Eur J Radiol; 1996 Nov; 23 Suppl 1():S6-9. PubMed ID: 9056157
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro.
Heinrich MC; Kuhlmann MK; Grgic A; Heckmann M; Kramann B; Uder M
Radiology; 2005 Jun; 235(3):843-9. PubMed ID: 15845795
[TBL] [Abstract][Full Text] [Related]
3. Effects of dimeric radiographic contrast medium iotrolan on Swine renal arteries: comparison with monomeric contrast media iohexol and iomeprol.
Heinrich M; Schneider G; Grgic A; Humke U; Kramann B; Uder M
Invest Radiol; 2004 Jul; 39(7):406-12. PubMed ID: 15194911
[TBL] [Abstract][Full Text] [Related]
4. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials.
Heinrich MC; Häberle L; Müller V; Bautz W; Uder M
Radiology; 2009 Jan; 250(1):68-86. PubMed ID: 19092091
[TBL] [Abstract][Full Text] [Related]
5. New non-ionic contrast: effects on the cardiovascular system.
Pagny JY; Gaux JC
Eur J Radiol; 1996 Nov; 23 Suppl 1():S2-5. PubMed ID: 9056156
[TBL] [Abstract][Full Text] [Related]
6. Iomeprol: current and future profile of a radiocontrast agent.
Katayama H; Spinazzi A; Fouillet X; Kirchin MA; Taroni P; Davies A
Invest Radiol; 2001 Feb; 36(2):87-96. PubMed ID: 11224756
[TBL] [Abstract][Full Text] [Related]
7. Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention.
Wessely R; Koppara T; Bradaric C; Vorpahl M; Braun S; Schulz S; Mehilli J; Schömig A; Kastrati A;
Circ Cardiovasc Interv; 2009 Oct; 2(5):430-7. PubMed ID: 20031753
[TBL] [Abstract][Full Text] [Related]
8. Nephropathy after administration of iso-osmolar and low-osmolar contrast media: evidence from a network meta-analysis.
Biondi-Zoccai G; Lotrionte M; Thomsen HS; Romagnoli E; D'Ascenzo F; Giordano A; Frati G
Int J Cardiol; 2014 Mar; 172(2):375-80. PubMed ID: 24502883
[TBL] [Abstract][Full Text] [Related]
9. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials.
Reed M; Meier P; Tamhane UU; Welch KB; Moscucci M; Gurm HS
JACC Cardiovasc Interv; 2009 Jul; 2(7):645-54. PubMed ID: 19628188
[TBL] [Abstract][Full Text] [Related]
10. Preclinical safety assessment of iomeprol for injection as contrast medium for myelography.
La Noce A; Bertani F; Lorusso V; Luzzani F; Tirone P; de Haën C
Eur J Radiol; 1994 May; 18 Suppl 1():S43-50. PubMed ID: 8020518
[TBL] [Abstract][Full Text] [Related]
11. Risk of contrast-medium-induced nephropathy in high-risk patients undergoing MDCT--a pooled analysis of two randomized trials.
Thomsen HS; Morcos SK
Eur Radiol; 2009 Apr; 19(4):891-7. PubMed ID: 19002467
[TBL] [Abstract][Full Text] [Related]
12. Effect of nonionic radiocontrast agents on the occurrence of contrast-induced nephropathy in patients with mild-moderate chronic renal insufficiency: pooled analysis of the randomized trials.
Sharma SK; Kini A
Catheter Cardiovasc Interv; 2005 Jul; 65(3):386-93. PubMed ID: 15926184
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with iomeprol in myelography and myelo-CT: clinical pharmacology and double-blind comparisons with iopamidol, iohexol, and iotrolan.
Katayama H; Heneine N; van Gessel R; Taroni P; Spinazzi A
Invest Radiol; 2001 Jan; 36(1):22-32. PubMed ID: 11176258
[TBL] [Abstract][Full Text] [Related]
14. Nonionic contrast media are less nephrotoxic than ionic contrast media to rat renal cortical slices.
Soejima K; Uozumi J; Kanou T; Fujiyama C; Masaki Z
Toxicol Lett; 2003 Jun; 143(1):17-25. PubMed ID: 12697376
[TBL] [Abstract][Full Text] [Related]
15. Iomeprol: a review of its use as a contrast medium.
Dooley M; Jarvis B
Drugs; 2000 May; 59(5):1169-86. PubMed ID: 10852647
[TBL] [Abstract][Full Text] [Related]
16. Contrast-induced acute kidney injury in patients with renal dysfunction undergoing a coronary procedure and receiving non-ionic low-osmolar versus iso-osmolar contrast media.
Alexopoulos E; Spargias K; Kyrzopoulos S; Manginas A; Pavlides G; Voudris V; Lerakis S; McLean DS; Cokkinos DV
Am J Med Sci; 2010 Jan; 339(1):25-30. PubMed ID: 19996728
[TBL] [Abstract][Full Text] [Related]
17. Nonionic contrast media iohexol and iomeprol decrease renal arterial tone: comparative studies on human and porcine isolated vascular segments.
Uder M; Humke U; Pahl M; Jansen A; Utz J; Kramann B
Invest Radiol; 2002 Aug; 37(8):440-7. PubMed ID: 12138360
[TBL] [Abstract][Full Text] [Related]
18. Nephrotoxic effects in high-risk patients undergoing angiography.
Aspelin P; Aubry P; Fransson SG; Strasser R; Willenbrock R; Berg KJ;
N Engl J Med; 2003 Feb; 348(6):491-9. PubMed ID: 12571256
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility and safety profile of iomeprol.
Rosati G
Eur J Radiol; 1994 May; 18 Suppl 1():S120-4. PubMed ID: 8020514
[TBL] [Abstract][Full Text] [Related]
20. Reversibility and time-dependency of contrast medium induced inhibition of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) conversion in renal proximal tubular cells in vitro: comparison of a monomeric and a dimeric nonionic iodinated contrast medium.
Heinrich M; Scheer M; Heckmann M; Bautz W; Uder M
Invest Radiol; 2007 Nov; 42(11):732-8. PubMed ID: 18030195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
